Nano cap Atossa Genetics (NASDAQ:ATOS) is up 227% premarket on increased volume in response to the FDA’s sign-off on expanded access to Endoxifen for the post-mastectomy treatment of a single premenopausal estrogen receptor-positive (ER+) breast cancer patient.
The patient received a three-week course oral Endoxifen prior to her surgery.
According to the company, Endoxifen prevents the ER from functioning, adding that recent research suggests that it also destroys the receptor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.